ReviewBioMed research international2013
What is recent in pancreatic cancer immunotherapy?
Review in BioMed research international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Cytotoxic effects of five Iranian medicinal plants on pancreatic cancer cell lines and investigation of induced changes in the expression of several key genes.BMC complementary medicine and therapies · 2025Article
- The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets.Frontiers in oncology · 2023Review
- Prognostic Values of Radiosensitivity Genes and CD19 Status in Gastric Cancer: A Retrospective Study Using TCGA Database.Pharmacogenomics and personalized medicine · 2020Article
- Transient and Local Expression of Chemokine and Immune Checkpoint Traps To Treat Pancreatic Cancer.ACS nano · 2017Article
- Novel REIC/Dkk-3-encoding adenoviral vector as a promising therapeutic agent for pancreatic cancer.Cancer gene therapy · 2016Article
- Trials of vaccines for pancreatic ductal adenocarcinoma: Is there any hope of an improved prognosis?Surgery today · 2016Review
- New targeted therapies in pancreatic cancer.World journal of gastroenterology · 2015Review
- Gastric cancer and the epoch of immunotherapy approaches.World journal of gastroenterology · 2015Review
- Pancreatic cancer, treatment options, and GI-4000.Human vaccines & immunotherapeutics · 2015Review
- Complex role for the immune system in initiation and progression of pancreatic cancer.World journal of gastroenterology · 2014Review
- Pancreatic cancer, treatment options, and GI-4000.Human vaccines & immunotherapeutics · 2014Review
- Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy.Human vaccines & immunotherapeutics · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) represents an unresolved therapeutic challenge, due to the poor prognosis and the reduced response to currently available treatments. Pancreatic cancer is the most lethal type of digestive cancers, with a median survival of 4-6 months. Only a small proportion of PC patients is curative by surgical resection, whilst standard chemotherapy for patients in advanced disease generates only modest effects with considerable toxic damages. Thus, new therapeutic approaches, specially specific treatments such as immunotherapy, are needed. In this paper we analyze recent preclinical and clinical efforts towards immunotherapy of pancreatic cancer, including passive and active immunotherapy approaches, designed to target pancreatic-cancer-associated antigens and to elicit an antitumor response in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.